AnGes Inc. (Ticker: 4563) announced that, based on the results of an independent data safety monitoring board assessment in the usa, there were no safety issues regarding the Phase 2a clinical trial of the Tie2 receptor agonist (AV-001) jointly developed with the Canadian biopharmaceutical company Vasomune Therapeutics (hereafter referred to as Vasomune), and a recommendation was made for the transition to the final cohort (highest dose).

The Tie2 receptor agonist is a treatment developed by Vasomune for diseases associated with vascular dysfunction.

It should be noted that there will be no impact on the consolidated results for the fiscal year ending December 2024 regarding these results.